Chong Kun Dang Pharmaceutical Corp. (KRX:185750)
South Korea flag South Korea · Delayed Price · Currency is KRW
85,500
+400 (0.47%)
Last updated: Jun 5, 2025

KRX:185750 Revenue

Chong Kun Dang Pharmaceutical had revenue of 400.96B KRW in the quarter ending March 31, 2025, with 10.91% growth. This brings the company's revenue in the last twelve months to 1.63T, down -2.39% year-over-year. In the year 2024, Chong Kun Dang Pharmaceutical had annual revenue of 1.59T, down -4.97%.

Revenue (ttm)
1,625.88B
Revenue Growth
-2.39%
P/S Ratio
0.69
Revenue / Employee
714.36M
Employees
2,276
Market Cap
1,126.55B

Revenue Chart

History

Fiscal Year End Revenue Change Growth
Dec 31, 20241,586.43B-82.97B-4.97%
Dec 31, 20231,669.40B181.06B12.17%
Dec 31, 20221,488.34B144.79B10.78%
Dec 31, 20211,343.56B40.55B3.11%
Dec 31, 20201,303.01B223.67B20.72%
Dec 31, 2019 Pro Pro Pro
Dec 31, 2018 Pro Pro Pro
Dec 31, 2017 Pro Pro Pro
Dec 31, 2016 Pro Pro Pro

Revenue Definition

Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.

Full Definition

Related Stocks

Company Name Revenue
Samsung Biologics 4,898.69B
Celltrion 3,662.23B
ALTEOGEN 151.65B
Yuhan 2,114.76B
SK Biopharmaceuticals 578.00B
HLB Co., Ltd. 74.64B
PharmaResearch 392.31B
LigaChem Biosciences 146.42B
Revenue Rankings